Abstract | OBJECTIVE: DESIGN: An open phase II observational trial of GnRH analogues. Serial measurements of gonadotrophins, sex hormones and tumour dimensions were made together with repeat biopsy when possible to assess the response to treatment. SETTING: The outpatient clinics of the Department of Medical Oncology at The Royal London, Royal Marsden and St Bartholomew's hospitals. SUBJECTS: INTERVENTION: MAIN OUTCOME MEASURES: Reduction in serum gonadotrophins and reduction in tumour dimensions. RESULTS: Six out of 17 patients (35%, 95% CI 12.6-58%) achieved a complete or partial remission which continues for a median of 20 months with no adverse effects. CONCLUSION:
|
Authors | C J Gallagher, R T Oliver, D H Oram, C G Fowler, P R Blake, B S Mantell, M L Slevin, H F Hope-Stone |
Journal | British journal of obstetrics and gynaecology
(Br J Obstet Gynaecol)
Vol. 98
Issue 10
Pg. 1037-41
(Oct 1991)
ISSN: 0306-5456 [Print] England |
PMID | 1751436
(Publication Type: Journal Article)
|
Chemical References |
- Gonadotropin-Releasing Hormone
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Aged, 80 and over
- Drug Evaluation
- Endometrial Neoplasms
(drug therapy)
- Female
- Gonadotropin-Releasing Hormone
(analogs & derivatives)
- Humans
- Middle Aged
- Prognosis
|